Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

The goal of this clinical study is to learn more about the long-term safety, effectiveness
and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel,
KITE-222, KITE-363, KITE-439, KITE-585, and KITE-718, in participants of Kite-sponsored
interventional studies.

Disease Sites:

Hematologic, Leukemia, Lymphoma, Pediatric Leukemia, Pediatric Lymphoma

Staging:

N/A

Age Group:

Both

Therapies:

Not Available

Drugs:

Not Available

Principal Investigator(s):

Kassim, Adetola

Scope:

International

Participating Institutions:

Vanderbilt University

Open Date:

07-08-2022

Trial Type:

Treatment

Protocol ID:

VICCCTT2170

National Clinical Trial ID:

NCT05041309

View Internal Documents

Eligibility

Ages Eligible for Study:

0 Years

Genders Eligible for Study:

BOTH

Accepts Healthy Volunteers?:

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Eligibility